8 results about "Neuroregulator" patented technology

The invention discloses a composition for improving immunity and delaying senescence and a preparation method thereof. Belongs to the technical field of functional health. The composition comprises the following components in parts by mass: 5-50 parts of collagen, 10-80 parts of paeonia ostii tea, 1-20 parts of an antioxidant, 3-10 parts of an intestinal microecology regulator and 1-3 parts of an energy metabolism and nerve regulator. According to the invention, through multi-system cooperation and multi-target intervention, dual effects of immune enhancement and senescence delay are realized. Through scientific compounding and a special process, the product has the advantages of stable components, uniform activity and good solubility. Animal experiments and theoretical models show that immune organs can be effectively protected, accumulation of aging markers is reduced, and a solution is provided for development of comprehensive anti-aging health products.

Methods and systems for providing stimulation therapy are disclosed. Embodiments of the system include an implantable stimulator and an external controller configured to control the implantable stimulator. A clinician can prescribe a set amount of stimulation therapy to a patient. The external controller is programmed with the prescription. As the patient uses the external controller and the stimulator device the external controller tracks the amount of stimulation the patient uses. Once the patient has used all of the prescribed therapy the patient may return to the clinician for a follow-up appointment.

The present disclosure is directed to a bio-feedback sensor in combination with AI and ML that can be implemented to optimize neuromodulation parameters for the management of a medical condition such a type II diabetes. The bio-feedback obtained by the sensors is optimized by the ML tools to predict and recommend the upregulation or downregulating the neuroregulators to modulate treatment. The algorithms could also learn to sense a life-threating pathological state, or bio-chemical imbalance, and in the case of diabetes a life-threating low blood sugar level the system overrides to stimulate the target fibers that control organs to regulate blood glucose levels.

The present disclosure is directed to kappa opioid receptor ligands and pharmaceutical compositions thereof and their utility as neurological modulators (e.g., anti-nociceptive agents, antidepressants, anxiolytics, antipruritics). Specifically, the disclosed kappa opioid ligands are G-protein biased kappa opioid agonists containing a core and three different arms as is shown in Formula (A) below.

This invention provides the application of neuregulin protein in the manufacture of drugs for preventing, treating, or delaying human heart failure, and methods for using such drugs. [Solution] The method includes: first examining the patient before treatment, wherein the examination includes detecting plasma levels of NT-proBNP or BNP; and subsequently providing appropriate treatment based on the examination results. If the examination results are within the optimal therapeutic range, the patient is suitable for treatment of heart failure by administering an effective dose of Neureglin.

The present disclosure relates to kappa opioid receptor ligands and pharmaceutical compositions thereof, and their utility as neurological modulators (e.g., antinociceptive agents, antidepressants, anxiolytic agents, antipruritic agents). Specifically, the disclosed kappa opioid ligands are G protein-biased kappa opioid agonists containing a core and three distinct arms, as shown in formula (A) below. TIFF2026507218000102.tif2335

Medicaments and methods for preventing, treating, or delaying heart failure with preserved ejection fraction in mammals are provided. The present invention provides the use of neuregulin in the manufacture of a medicament for preventing, treating, or delaying heart failure with preserved ejection fraction in a mammal, and a pharmaceutical preparation for preventing, treating, or delaying heart failure with preserved ejection fraction in a mammal, the pharmaceutical preparation comprising an effective amount of neuregulin.

This invention belongs to the field of deuterated labeled compound synthesis technology, and discloses a method for deuterating indole compounds and its application. The deuteration method of this invention includes the following steps: mixing an indole compound, a transition metal catalyst, a complex ligand, an additive, and a deuteration solvent, reacting to obtain a deuterated product; the complex ligand includes a first ligand and a second ligand; the first ligand includes a lactam compound; the second ligand includes a pyridone compound; and the deuteration solvent includes deuterated acetic acid. The deuteration method of this invention achieves highly selective hydrogen-deuterium exchange at multiple sites on the indole ring of indole compounds (especially the difficult-to-modify C4-C7 sites) through the synergistic effect of the catalyst, the dual ligand, and the deuteration solvent system. Furthermore, it can be applied to the deuteration synthesis of drugs such as the anti-inflammatory drug indomethacin, the cancer adjuvant therapy drug tropisetron, and the neuromodulator melatonin, providing key technical support for the development of deuterated drugs.